Defensin-Rich Platelets Drive Pro-Tumorigenic Programs in Pancreatic Adenocarcinoma
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262210898 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Jonathan Gonzalez-Ruiz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ciencias de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City 09310, Mexico. Hauptthemen laut MEDLINE: Blood Platelets, Pancreatic Neoplasms, alpha-Defensins, Carcinoma, Pancreatic Ductal. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaría de Ciencia, Humanidades, Tecnología e Innovación, Consejo Nacional de Humanidades, Ciencias y Tecnologías CONAHCYT, Mexico, CONAHCYT doctoral scholarship.
Abstract (Originalsprache)
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive and lethal malignancies, driven by late diagnosis, limited therapeutic options, and high metastatic potential. Beyond their canonical roles in hemostasis, platelets have emerged as active modulators of tumor progression and promising noninvasive biomarkers. Among platelet-associated molecules, α-defensins, particularly Defensin Alpha 1/3 (DEFA1/3), have been implicated in inflammation and immunity; however, their contribution to PDAC pathogenesis remains unclear. We combined bioinformatic analysis of platelet transcriptomes with functional and in vivo zebrafish xenograft validation to investigate the impact of DEFA1/3 on PDAC aggressiveness. DEFA1/3 was significantly upregulated in PDAC-derived platelets. Defensin-enriched platelet-like particles (defensin-rich platelets, DRPs) and recombinant DEFA1/3 enhanced pancreatic cancer cell proliferation, migration, and three-dimensional growth in vitro and promoted tumor dissemination in zebrafish xenografts. Transcriptomic profiling revealed the upregulation of SPARC, KDM6A, and GATA6, whereas clinical data from The Cancer Genome Atlas (TCGA)-PDAC linked high DEFA1/3 expression to poor survival, increased immune infiltration, and activation of epithelial–mesenchymal transition (EMT). Platelet-derived DEFA1/3 acts as a functional modulator of PDAC progression, linking platelet granule content to tumor aggressiveness and highlighting a potential biomarker and therapeutic target within the platelet–tumor axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ciencias de la Salud, Universidad Autónoma Metropolitana-Iztapalapa, Mexico City 09310, Mexico.
- Laboratorio de Genómica Funcional del Cáncer, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.
- Laboratorio de Epigenética, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.
ORCID-Profile: Jonathan Gonzalez-Ruiz, Miryam Sarmiento-Casas, Ivan Bahena-Ocampo, Magali Espinosa, Gisela Ceballos-Cancino, Karla Vazquez-Santillan, Vilma Maldonado, Jorge Melendez-Zajgla
Förderung
- Secretaría de Ciencia, Humanidades, Tecnología e Innovación
- Consejo Nacional de Humanidades, Ciencias y Tecnologías CONAHCYT, Mexico
- CONAHCYT doctoral scholarship
Zitieren
APA
Gonzalez-Ruiz, J., Sarmiento-Casas, M., Bahena-Ocampo, I., Espinosa, M., Ceballos-Cancino, G., Vazquez-Santillan, K., Maldonado, V., & Melendez-Zajgla, J. (2025). Defensin-Rich Platelets Drive Pro-Tumorigenic Programs in Pancreatic Adenocarcinoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262210898
Vancouver
Gonzalez-Ruiz J, Sarmiento-Casas M, Bahena-Ocampo I, Espinosa M, Ceballos-Cancino G, Vazquez-Santillan K, et al. Defensin-Rich Platelets Drive Pro-Tumorigenic Programs in Pancreatic Adenocarcinoma. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262210898
BibTeX
@article{GonzalezRuiz2025,
author = {Gonzalez-Ruiz, Jonathan and Sarmiento-Casas, Miryam and Bahena-Ocampo, Ivan and Espinosa, Magali and Ceballos-Cancino, Gisela and Vazquez-Santillan, Karla and Maldonado, Vilma and Melendez-Zajgla, Jorge},
title = {Defensin-Rich Platelets Drive Pro-Tumorigenic Programs in Pancreatic Adenocarcinoma},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262210898}
}
EUVIMED